Effect of NRAMP1 gene polymorphism on levels of (TNF-α1and IL-1β) cytokines in cutaneous Leishmaniasis patients in Iraq

Öz

Background: Cutaneous leishmaniasis (CL) is vector-borne disease. and endemics in most regions of Iraq especially with poor populations. "Natural resistance-associated macrophage protein 1 (NRAMP1)" gene play an essential role in susceptibility to CL and disease pathology, NRAMP1 influences a production and activation of pro-inflammatory cytokines like IL-1β and TNF-α. Pro- and anti-inflammatory cytokines play an essential role in susceptibility/resistance and the immunopathogenesis of Leishmania infection. These cytokines are crucial factors in the initiation and enhances of protective immunity against Leishmania infection. This study aimed to determine effect of polymorphism in NRAMP1 genes on cytokines secretion and their effect in susceptibility to CL infection.

Materials and Methods: Samples of blood were collected from patients (n: 60) with CL and apparently healthy controls (n: 32). Polymorphism of Nramp1 (D543N) detected by PCR-RFLP technique in patients and control groups while (TNF-α and IL-1β) cytokine concentrations detected by ELISA technique using a quantitative sandwich enzyme immunoassay technique.

Results: Results indicate to effect of Nramp1 gene polymorphism on levels of (IL-1β and TNF-α) cytokines and this a clearly recorded in present study were A allele is associated with lower levels of (TNF-α and IL-1β) in patients and control groups compression to that absorbed in allele G with statically significant (p ≤ 0.05).

Conclusions: Cytokines (IL-1β and TNF-α) plays an essential  role in the resolution of CL infection,  were its concentration  in patients serum of all age groups were significant increase in comparison to that observed in their control groups. In polymorphisms of Nramp1 (D543N) gene, were A allele is associated with lower levels of (IL-1β and TNF-α) compression to that  absorbed in allele G, and this decreased production may be associated with susceptibility and proliferation of parasites in the macrophage.

Anahtar Kelimeler

• Cutaneous leishmaniosis,NRAMP1polymorphisms,TNF-α and IL-1β,Cytokine

Kaynakça

1. 1. Ahmed S, Colmenares M, Soong L, Goldsmith-Pestana K, Munstermann L, Molina R, et al. Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infection and immunity. 2003;71(1):401-10.
2. 2. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. Journal of Antimicrobial Chemotherapy. 2004;53(2):158-66.
3. 3. Tripathi P, Singh V, Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunology & Medical Microbiology. 2007;51(2):229-42.
4. 4. Vidal S, Tremblay ML, Govoni G, Gauthier S, Sebastiani G, Malo D, et al. The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. Journal of Experimental Medicine. 1995;182(3):655-66.
5. 5. Mulero V, Searle S, Jenefer M, Brock JH. Solute carrier 11a1 (Slc11a1; formerly Nramp1) regulates metabolism and release of iron acquired by phagocytic, but not transferrin-receptor-mediated, iron uptake. Biochemical Journal. 2002;363(1):89-94.
6. 6. Mackenzie B, Hediger MA. SLC11 family of H+-coupled metal-ion transporters NRAMP1 and DMT1. Pflügers Archiv. 2004;447(5):571-9.
7. 7. Courville P, Chaloupka R, Cellier M. Recent progress in structure–function analyses of Nramp proton-dependent metal-ion transporters This paper is one of a selection of papers published in this Special Issue, entitled CSBMCB—Membrane Proteins in Health and Disease. Biochemistry and Cell Biology. 2006;84(6):960-78.
8. 8. Taype C, Castro J, Accinelli R, Herrera-Velit P, Shaw M, Espinoza J. Association between SLC11A1 polymorphisms and susceptibility to different clinical forms of tuberculosis in the Peruvian population. Infection, Genetics and Evolution. 2006;6(5):361-7.

9. 9. Blackwell JM, Searle S, Goswami T, Miller EN. Understanding the multiple functions of Nramp1. Microbes and infection. 2000;2(3):317-21.
10. 10. Ganz T. Iron in innate immunity: starve the invaders. Current opinion in immunology. 2009;21(1):63-7.
11. 11. Belosevic M, Davis C, Meltzer M, Nacy C. Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. The Journal of Immunology. 1988;141(3):890-6.
12. 12. Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian Journal of Medical Research. 2004;119(6):238.
13. 13. Santos D, Campos TM, Saldanha M, Oliveira SC, Nascimento M, Zamboni DS, et al. IL-1β production by intermediate monocytes is associated with immunopathology in cutaneous leishmaniasis. Journal of Investigative Dermatology. 2017.
14. 14. Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro V, et al. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clinical and diagnostic laboratory immunology. 2002;9(2):251-6.
15. 15. Team RC. R Foundation for Statistical Computing; Vienna, Austria: 2014. R: A language and environment for statistical computing. 2015:2013.
16. 16. Al-Aubaidi IK. Serum Cytokine Production in Patients with Cutaneous Leishmaniasis Before and After Treatment. Iraqi Journal of Medical Sciences. 2011;9(1).
17. 17. Kocyigit A, Gur S, Gurel MS, Bulut V, Ulukanligil M. Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis. Infection and immunity. 2002;70(12):6589-91.
18. 18. Roberts WL, Rainey PM. Antileishmanial activity of sodium stibogluconate fractions. Antimicrobial Agents and Chemotherapy. 1993;37(9):1842-6.
19. 19. Sodhi A, Pai K, Singh RK, Singh SM. Activation of human NK cells and monocytes with cisplatin in vitro. International journal of immunopharmacology. 1990;12(8):893-8.
20. 20. Beebe AM, Mauze S, Schork NJ, Coffman RL. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity. 1997;6(5):551-7.
21. 21. García M, Monzote L, Montalvo AM, Scull R. Screening of medicinal plants against Leishmania amazonensis. Pharmaceutical biology. 2010;48(9):1053-8.
22. 22. Murray H, Oca M, Granger A, Schreiber R. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. Journal of Clinical Investigation. 1989;83(4):1253.
23. 23. Rais S, Perianin A, Lenoir M, Sadak A, Rivollet D, Paul M, et al. Sodium stibogluconate (Pentostam) potentiates oxidant production in murine visceral leishmaniasis and in human blood. Antimicrobial agents and chemotherapy. 2000;44(9):2406-10.
24. 24. Canonne-Hergaux F, Calafat J, Richer E, Cellier M, Grinstein S, Borregaard N, et al. Expression and subcellular localization of NRAMP1 in human neutrophil granules. Blood. 2002;100(1):268-75.
25. 25. Kim J, Lee S, Lee S, Sin C, Shim J, In K, et al. NRAMP1 genetic polymorphisms as a risk factor of tuberculous pleurisy. The International Journal of Tuberculosis and Lung Disease. 2003;7(4):370-5.
26. 26. Blackwell JM, Searle S, Mohamed H, White JK. Divalent cation transport and susceptibility to infectious and autoimmune disease: continuation of the Ity/Lsh/Bcg/Nramp1/Slc11a1 gene story. Immunology letters. 2003;85(2):197-203.
27. 27. Fritsche G, Nairz M, Werner ER, Barton HC, Weiss G. Nramp1‐functionality increases iNOS expression via repression of IL‐10 formation. European journal of immunology. 2008;38(11):3060-7.
28. 28. Nugraha J, Anggraini R. NRAMP1 polymorphism and susceptibility to lung tuberculosis in Surabaya, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health. 2011;42(2):338.
29. 29. Wessling-Resnick M. Nramp1 and other transporters involved in metal withholding during infection. Journal of Biological Chemistry. 2015;290(31):18984-90.